1Kane, J, Honigfeld, G, Singer, J, Meltzer, H.Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796.
2Horacek, J, Bubenikova-Valesova, V, Kopecek, Met al.Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20: 389–409.
3Meltzer, HY, Alphs, L, Green, AIet al.Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60:82–91.
4Tandon, R, Fleischhacker, WW.Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145–155.
5Remington, G, Saha, A, Chong, SA, Shammi, C.Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843–872.
6Henderson, DC, Cagliero, E, Gray, Cet al.Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975–981.
7Chung, C, Remington, G.Predictors and markers of clozapine response. Psychopharmacology (Berl) 2005;179: 317–335.
8Pirmohamed, M, Williams, D, Madden, S, Templeton, E, Park, BK.Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272: 984–990.
9Ozdemir, V, Kalow, W, Okey, ABet al.Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine J Clin Psychopharmacol 2001;21:603–607.
10Eap, CB, Bender, S, Jaquenoud Sirot, Eet al.Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214–219.
11Djordjevic, N, Ghotbi, R, Jankovic, S, Aklillu, E.Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C>A polymorphism. Eur J Clin Pharmacol 2010;66:697–703.
12Potkin, SG, Bera, R, Gulasekaram, Bet al.Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl. B):133–136.
13Kronig, MH, Munne, RA, Szymanski, Set al.Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152: 179–182.
14Miller, DD, Fleming, F, Holman, TL, Perry, PJ.Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl. B): 117–121.
15Corchero, J, Pimprale, S, Kimura, S, Gonzalez, FJ.Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001;11:1–6.
16Zhou, SF, Wang, B, Yang, LP, Liu, JP.Structure function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268–354.
17Murayama, N, Soyama, A, Saito, Yet al.Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308:300–306.
18Soyama, A, Saito, Y, Hanioka, Net al.Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005;20:24–33.
19Sachse, C, Bhambra, U, Smith, Get al.Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68–76.
20Arranz, MJ, Munro, J, Sham, Pet al.Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32:93–99.
21Souza, RP, de Luca, V, Meltzer, HY, Lieberman, JA, Kennedy, JL.Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010;20:274–276.
22Honigfeld, G, Patin, J.Predictors of response to clozapine therapy. Psychopharmacology (Berl) 1989;99(Suppl): S64–S67.
23Honer, WG, Macewan, GW, Kopala, Let al.A clinical study of clozapine treatment and predictors of response in a Canadian sample. Can J Psychiatry 1995;40:208–211.
24Umbricht, DS, Wirshing, WC, Wirshing, DAet al.Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63:420–424.
25Lieberman, JA, Safferman, AZ, Pollack, Set al.Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744–1752.
26Mancama, D, Arranz, MJ, Kerwin, RW.Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 2002;16:317–324.
27Arranz, MJ, Munro, J, Birkett, Jet al.Pharmacogenetic prediction of clozapine response. Lancet 2000;355: 1615–1616.
28Hwang, R, Shinkai, T, De Luca, Vet al.Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005;181:179–187.
29Lieberman, JA, Kane, JM, Safferman, AZet al.Predictors of response to clozapine. J Clin Psychiatry 1994;55(Suppl. B):126–128.
30Gross, A, Joutsiniemi, SL, Rimon, R, Appelber, GB.Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry 2004;37:119–122.
31Swen, JJ, Nijenhuis, M, de Boer, Aet al.Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 2011;89:662–673.
32Kootstra-Ros, JE, Smallegoor, W, Van der Weide, J.The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005;42:216–219.
33Jaquenoud Sirot, E, Knezevic, B, Morena, GPet al.ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29:319–326.
34Van der Weide, J, Steijns, LS, Van Weelden, MJ.The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169–172.
35Schulte, PF.Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683–688.
37APA. Diagnostic and statistical manual of mental disorders. 4th edn. Text Revision (DSM-IV-TR). Washington D.C.: American Psychiatric Association, 2000.
38Overall, JE, Gorham, DR.The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
39Guy, W.ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976.
40Mioshi, E, Dawson, K, Mitchell, J, Arnold, R, Hodges, JR.The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078–1085.
41WHO. WHODAS II Disability Assessment Schedule: 12-Item interviewer administered version. Geneva: World Health Organization, 2001.
42Pennebaker, JW, Susman, JR.Disclosure of traumas and psychosomatic processes. Soc Sci Med 1988;26:327–332.
43Rabinowitz, J, Levine, SZ, Brill, N, Bromet, EJ.The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res 2007;90:255–257.
44Wongsinsup, C, Taesotikul, W, Kaewvichit, S, Sangsrijan, S, Sangsrija, S.Determination of clozapine in human plasma by high – performance liquid chromatography with UV – VIS Detector. CMU J Nat Sci 2010;9:29–37.
45Conley, RR, Carpenter, WT Jr, Tamminga, CA.Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243–1247.
46Buckley, P, Miller, A, Olsen, J, Garver, D, Miller, DD, Csernansky, J.When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001;27:615–628.
47Gauderman, WJ.Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002;155:478–484.
48Purcell, S, Neale, B, Todd-Brown, Ket al.PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–575.
49Semiz, UB, Cetin, M, Basoglu, Cet al.Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1330–1336.
52Estellat, C, Torgerson, DJ, Ravaud, P.How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol 2009;23:291–303.
53Burns, T.Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl 2007;50:s1–s6.
54Tiwari, AK, Deshpande, SN, Lerer, B, Nimgaonkar, VL, Thelma, BK.Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism Pharmacogenomics J 2007;7:305–311.
55Perry, PJ, Bever, KA, Arndt, S, Combs, MD.Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998;44: 733–738.
56Dratcu, L, Grandison, A, Mckay, G, Bamidele, A, Vasudevan, V.Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 2007;14:314–318.
57Mcevoy, JP, Freudenreich, O, Wilson, WH.Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125–129.
58de Leon, J, Arranz, MJ, Ruano, G.Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008;28:599–617.
61Stefansson, H, Ophoff, RA, Steinberg, Set al.Common variants conferring risk of schizophrenia. Nature 2009;460:744–747.
62Sullivan, PF, Kendler, KS, Neale, MC.Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–1192.
63Prasad, S, Semwal, P, Deshpande, S, Bhatia, T, Nimgaonkar, VL, Thelma, BK.Molecular genetics of schizophrenia: past, present and future. J Biosci 2002;27:35–52.
64Jerling, M, Merle, Y, Mentre, F, Mallet, A.Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997;44:447–453.